NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will participate in the M-Vest Advances in Mental
Health, Psychedelic and Non-Psychedelic Virtual Conference on
September 22nd and the
Cantor Virtual Global Healthcare Conference, September 27th-30th,
2021.
M-Vest Advances in Mental Health, Psychedelic and
Non-Psychedelic Virtual Conference
- Raj Mehra, Ph.D., Chairman and CEO will participate in a
Depression Panel titled: "Spravato opened the door, what comes
next?", on Wednesday, September
22nd at 2:00pm
ET.
- The panel discussion will be moderated by Jason McCarthy, Ph.D., Head of Biotechnology
Research at Maxim Group.
- For conference registration:
https://m-vest.com/events/advances-in-mental-health
Cantor Virtual Global Healthcare Conference
- Raj Mehra, Ph.D., Chairman and CEO, will participate in a
fireside chat on Wednesday, September
29th at 10:00am ET
and host 1x1 meetings via conference calls.
- The fireside chat will be moderated by Charles C. Duncan, Ph.D., Senior Biotechnology
Analyst at Cantor Fitzgerald.
- For webcast link and replay:
https://wsw.com/webcast/cantor12/seel/2075290
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral
sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other
psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-in-september-301371732.html
SOURCE Seelos Therapeutics, Inc.